Immunophenotypic Analysis in Early Müllerian Serous Carcinogenesis. (September 2015)

• Record Type: Journal Article
• Authors: Nafisi, Houman; Ghorab, Zeina; Ismill, Nadia; Dubé, Valerie; Plotkin, Anna; Han, Guangming; Cesari, Matthew; Lu, Fang-I; Saad, Reda; Khalifa, Mahmoud; Nofech-Mozes, Sharon
• Is Part Of: International journal of gynecological pathology. Volume 34:Number 5(2015:Sep.)
• Publication Date: 2015-09
• Subjects: Gynecologic pathology -- Periodicals; Gynecology -- Periodicals; Generative organs, Female -- Diseases -- Periodicals; 618.10705
• DOI: 10.1097/PGP.0000000000000179
• Languages: English
• ISSNs: 0277-1691

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <p>Studies on the immunophenotypes of early forms of serous carcinoma arising from female genital tract are limited. We aimed to examine p53, p16<sup>Ink4a</sup>, estrogen receptor (ER), progesterone receptor (PR), ERBB2, WT1, and Ki-67 protein expression in endometrial intraepithelial carcinoma (n=29), serous tubal intraepithelial lesion (n=4) and carcinoma (STIC, n=10), and the putative precursor p53 signature (n=11). Among endometrial intraepithelial carcinoma, 80% demonstrated p53 overexpression and 10% were consistent with a null phenotype. p16<sup>Ink4a</sup> immunostaining were observed in all endometrial intraepithelial carcinoma cases. ER, PR, ERBB2, and WT1 were positive in 54%, 25%, 11%, and 18% of cases, respectively. STIC cases demonstrated p53 overexpression and null phenotype in 90% and 10%, respectively. All STIC cases were p16<sup>Ink4a</sup> and WT1 positive, whereas ER and PR were positive in 70% and 20%, respectively. All STICs were negative for ERBB2. Among serous tubal intraepithelial lesion cases, 75% demonstrated p53 overexpression and 25% a null phenotype. p53 was positive in all 11 p53 signature cases, whereas p16<sup>Ink4a</sup> was universally negative. Finally, ER and PR were positive in 100% and 73% of p53 signature cases, respectively. These results suggest that p16<sup>Ink4a</sup> has a role in early Müllerian serous carcinogenesis but is absent in the earliest noncommitted lesion. p16<sup>Ink4a</sup> immunohistochemistry can be used as an adjunct confirmatory tool in p53-null cases with limited surface area.</p> </sec> </abstract>